Navigation Links
World Debut for BSP's HyperQ Stress System: 57th Annual American College of Cardiology Meeting 2008

TEL AVIV, Israel, March 25 /PRNewswire/ -- BSP Ltd. (, an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of ischemic heart disease, will be launching their HyperQ(TM) Stress System in the US during the 57th Annual ACC 08 Meeting in Chicago, IL.

The HyperQ(TM) is cutting-edge technology implemented in an innovative stress-test system, offering highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic heart disease patients.

The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking. To date, more than 3500 patients in Israel, Europe and the US have been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing in the setting of private offices and hospital clinics. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD.

The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient settings, outpatient cardiology departments, private doctor offices and major research centers.

Further applications on the company's scope, based on the same core technology, include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; periodic check-up systems, and the implementation of the HyperQ(TM) technology in implantable cardiac devices such as pacemakers and defibrillators.

Dr. Amir Beker, CEO of BSP says, "BSP's HyperQ(TM) technology is a revolutionary solution to today's most fatal pathology. The HyperQ(TM) Stress System is a non-invasive solution that will improve the standard of care for cardiac patients and at the same time will help reduce unnecessary costly and potentially harmful procedures. The HyperQ(TM) Stress System thus addresses dire needs of private and national healthcare systems to balance the immense costs of cardiac diagnosis and monitoring, while decreasing the risk of further, often invasive, tests for cardiac patients".

About BSP

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange.

Contact: Dr. Amir Beker, +972-3-6474840,

SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nanoscience will change the way we think about the world
2. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
4. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
5. Royea Joins Eklin Medical Systems as VP of Worldwide Sales
6. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
7. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
8. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
9. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
10. World Glaucoma Day Set for March 6th
11. Cascade Microtech Introduces Worlds First 45 nm-capable DC/RF Parametric Probe Card Solutions, Lowers Cost of Ownership
Post Your Comments:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):